# Study in Japan and Ex-Japan to Characterize the Pharmacokinetic and Pharmacodynamic Response to Orteronel (TAK-700) in Chemotherapy-Naive Participants With Castration-Resistant Prostate Cancer

> **NCT01666314** · PHASE1,PHASE2 · COMPLETED · sponsor: **Millennium Pharmaceuticals, Inc.** · enrollment: 137 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Orteronel
- **DRUG:** Orteronel Placebo
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT01666314
- **Lead sponsor:** Millennium Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-08-20
- **Primary completion:** 2013-09-12
- **Final completion:** 2016-09-01
- **Target enrollment:** 137 (ACTUAL)
- **Last updated:** 2018-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01666314

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01666314, "Study in Japan and Ex-Japan to Characterize the Pharmacokinetic and Pharmacodynamic Response to Orteronel (TAK-700) in Chemotherapy-Naive Participants With Castration-Resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01666314. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*